ATE176868T1 - Stabilisierte aufbereitung monoklonaler menschlicher cln-igg antikörper - Google Patents

Stabilisierte aufbereitung monoklonaler menschlicher cln-igg antikörper

Info

Publication number
ATE176868T1
ATE176868T1 AT92915866T AT92915866T ATE176868T1 AT E176868 T1 ATE176868 T1 AT E176868T1 AT 92915866 T AT92915866 T AT 92915866T AT 92915866 T AT92915866 T AT 92915866T AT E176868 T1 ATE176868 T1 AT E176868T1
Authority
AT
Austria
Prior art keywords
igg antibodies
monoclonal human
stabilized preparation
state
monoclonal antibody
Prior art date
Application number
AT92915866T
Other languages
English (en)
Inventor
Hideaki Hagiwara
Hideo Yuasa
Yasunori Yamamoto
Original Assignee
Hagiwara Yoshihide
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16495593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE176868(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hagiwara Yoshihide filed Critical Hagiwara Yoshihide
Application granted granted Critical
Publication of ATE176868T1 publication Critical patent/ATE176868T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT92915866T 1991-07-20 1992-07-17 Stabilisierte aufbereitung monoklonaler menschlicher cln-igg antikörper ATE176868T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3204743A JP2966592B2 (ja) 1991-07-20 1991-07-20 安定化されたヒトモノクローナル抗体製剤

Publications (1)

Publication Number Publication Date
ATE176868T1 true ATE176868T1 (de) 1999-03-15

Family

ID=16495593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92915866T ATE176868T1 (de) 1991-07-20 1992-07-17 Stabilisierte aufbereitung monoklonaler menschlicher cln-igg antikörper

Country Status (6)

Country Link
EP (1) EP0597101B1 (de)
JP (1) JP2966592B2 (de)
AT (1) ATE176868T1 (de)
AU (1) AU662010B2 (de)
DE (1) DE69228474T2 (de)
WO (1) WO1993001835A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1082368C (zh) * 1995-03-21 2002-04-10 应用研究系统Ars股份公司 人绒毛膜促性腺激素液体制剂
WO1996029095A1 (en) * 1995-03-21 1996-09-26 Applied Research Systems Ars Holding N.V. Hcg liquid formulations
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
SI0972520T1 (sl) * 1997-01-30 2006-02-28 Bioph Biotech Entw Pharm Gmbh Liofiliziran sestavek humanega kostnega morfogenetskega proteina MP52
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
AU2001277781A1 (en) * 2000-08-11 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP2311489A3 (de) 2002-02-14 2013-08-21 Chugai Seiyaku Kabushiki Kaisha Formularierung Antikörper-enthaltender Lösungen die einen Zucker als Stabilisator beinhalten.
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
EP3006463A1 (de) 2003-10-01 2016-04-13 Kyowa Hakko Kirin Co., Ltd. Verfahren zur stabilisierung von antikörpern und stabilisierte antikörperzubereitung vom lösungstyp
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
TWI398272B (zh) * 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
BR122019026701B1 (pt) * 2012-03-26 2023-01-24 Sanofi Formulações de agentes de ligação à base de igg4 estáveis, kit, e dispositivo ou recipiente pré-cheios
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5347515A (en) * 1976-10-13 1978-04-28 Green Cross Corp:The Gamma-globulin pharmaceutical preparation for intravenous injection
JPS56127320A (en) * 1980-03-10 1981-10-06 Mochida Pharmaceut Co Ltd Gamma-globulin pharmaceutical
US4808621A (en) * 1986-07-07 1989-02-28 Warner-Lambert Company Trans-6-[2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl]- or ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
JPS6388197A (ja) * 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
DE69029765T2 (de) * 1989-07-24 1997-05-15 Bayer Ag Stabilisierung von hochgereinigten Proteinen

Also Published As

Publication number Publication date
EP0597101B1 (de) 1999-02-24
JP2966592B2 (ja) 1999-10-25
EP0597101A4 (en) 1994-06-15
WO1993001835A1 (en) 1993-02-04
DE69228474T2 (de) 1999-06-24
EP0597101A1 (de) 1994-05-18
JPH0525058A (ja) 1993-02-02
AU662010B2 (en) 1995-08-17
AU2330592A (en) 1993-02-23
DE69228474D1 (de) 1999-04-01

Similar Documents

Publication Publication Date Title
ATE176868T1 (de) Stabilisierte aufbereitung monoklonaler menschlicher cln-igg antikörper
Finkelstein et al. Pathogenesis of experimental cholera: biologic activities of purified procholeragen A
ATE122357T1 (de) Polypeptide mit hormonwachstumsbefreiender wirkung.
IE823046L (en) Stabilised interferon formulations
ZA876807B (en) Monoclonal antibodies against human tumor necrosis factor(tnf),and use thereof
ATE112687T1 (de) Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
EP0284587A3 (de) Synthetische Peptid-Antigene für den Nachweis von HIV-1-Infektionen
EP0863210A3 (de) Künstliches Immunglobulinkombinierendes Protein
Chupin et al. Antagonistic effect of LH on FSH-induced superovulation in cattle
YU46189B (sh) Monoklonska antitela i antigen za karcinome pluća čoveka koji ne pripadaju tipu "malih ćelija"
OA08749A (fr) Vaccins dont l'épitope caractéristique est incorporé dans une protéine de picornavirus, notamment de poliovirus.
ATE24018T1 (de) Polysaccharid-antigen aus streptococcus und impfstoffe.
IL132414A0 (en) Type alpha platelet derived growth factor receptor gene
RU95112690A (ru) Препарат интерферона
ATE174794T1 (de) Parenteral anzuwendende aminosäuren enthaltende zubereitungen zur bekämpfung von hypotension und verwandten pathologien
DE3751319D1 (de) VERWENDUNG UND ZUSAMMENSETZUNG ZUR VERBESSERUNG DES "TARGETING" VON ANTIKöRPERN, ANTIKöRPERTEILEN, SOWIE KONJUGATE DERSELBEN.
ATE164311T1 (de) Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten
FR2577048B1 (fr) Reactif pour le dosage par hemagglutination des anticorps contre les toxines bacteriennes, procede de preparation et son application
ES2060695T3 (es) Concentrados terapeuticos de igm.
AU5435990A (en) Monoclonal antibodies to human glutathione s transferase pi
KR900700079A (ko) 누출방지 리포좀 제제
JPS6461499A (en) Monoclonal antibody to human papilloma viruses 16 type e7 protein, and production and use thereof
MA21448A1 (fr) Procede de preparation de structures peptidiques et immunogenes les contenant destines au controle de la fertilite.
EP0254845A3 (de) Immun-Stimulation mit Chondroitin-sulfat
FI874273A (fi) Uudet monoklonaaliset vasta-aineet IFN-omegalle, niiden valmistusmenetelmät ja niiden käyttö IFN-omegan puhdistamiseen ja osoittamiseen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee